Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env
Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env
复制标题
DOI：
10.1182/blood-2003-01-0110
复制
发表时间：
2003-07-01
期刊：
影响因子：
20.3
通讯作者：
Okuda, K
中科院分区：
文献类型：
--
作者：
Xin, KQ;Hoshino, Y;Okuda, K
本研究探讨经基因改造的口服乳酸乳球菌(L乳杆菌)是否可用作艾滋病毒疫苗。L乳汁具有免疫原性，口服时极其安全。我们构建了在细胞表面表达HIV包膜蛋白的重组L乳杆菌载体。用该载体口服免疫后，可诱导高水平的HIV特异性血清抗体和粪便抗体。在区域淋巴结和脾中也产生了细胞介导的免疫反应。树突状细胞很容易被L乳杆菌感染，似乎在这些免疫反应的发展中发挥了潜在的作用。通过用表达HIV Env的痘苗病毒攻击小鼠，证明了该疫苗策略的保护效果。他们的病毒载量比对照组小鼠低350倍。这些发现支持以L乳汁为基础的艾滋病毒疫苗的进一步开发。(C)2003年，由美国血液病学会提供。
This study investigates whether genetically modified orally administered Lactococcus lactis (L lactis) could be used as an HIV vaccine. L lactis is immunogenic and extremely safe when delivered orally. We created a recombinant L lactis vector expressing the envelope protein of HIV on its cell surface. Oral immunization with this vector induced high levels of HIV-specific serum IgG and fecal IgA antibodies. Cell-mediated immune responses also were generated in both the regional lymph nodes and the spleen. Dendritic cells are readily infected by L lactis and appear to play a potential role in mediating the development of these immune responses. The protective efficacy of this vaccine strategy was demonstrated by challenging mice intraperitoneally with an HIV Env-expressing vaccinia virus. Their viral loads were 350-fold lower than those of control mice. These findings support the further development of L lactis-based HIV vaccines. (C) 2003 by The American Society of Hematology.